{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:39:50Z","timestamp":1793147990669,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["ME-1408-19894"],"award-info":[{"award-number":["ME-1408-19894"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the persistence and effectiveness of TNF inhibitors (TNFi) vs non-TNFi among newly diagnosed JIA patients after initiation of biologic DMARD (bDMARD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using longitudinal patient-level data extracted from electronic medical records in a large Midwestern paediatric hospital from 2009 to 2018, we identified JIA patients initiating TNFi and non-TNFi treatment. Treatment effectiveness was assessed based on disease activity. Inverse probability of treatment weighting of propensity score was used to estimate the treatment effectiveness and Kaplan\u2013Meier analyses were conducted to assess persistence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 667 JIA patients, most (92.0%) were prescribed one of the class of TNFi as their initial biologic treatment. Etanercept was the most frequently prescribed (67.1%) treatment, followed by adalimumab (27.5%). Only around 5% of patients were prescribed off-label bDMARDs as their first-course treatment; however, &amp;gt;20% were prescribed off-label biologics as their second-course therapy. Some 7.2% of patients received four or more bDMARDs. The median persistence of the first-course bDMARD is 320\u2009days, with TNFi being significantly longer than the non-TNFi (395 vs 320\u2009days, P\u2009=\u20090.010). The clinical Juvenile Disease Activity Score (cJADAS) reduction of TNFi users (6.6, 95% CI 5.7, 7.5) was significant greater compared with non-TNFi users (3.0, 95% CI 1.5, 4.6, P\u2009&amp;lt;\u20090.0001) at 6-month follow-up visit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Persistence was significantly longer among patients initiating TNFi as their first biologic therapy than those receiving non-TNFi. Patients receiving TNF therapy had significant greater reduction of cJADAS at the 6-month follow-up visit compared with patients in the non-TNF cohort.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa877","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T03:55:56Z","timestamp":1607486156000},"page":"4063-4073","source":"Crossref","is-referenced-by-count":14,"title":["Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4418-7079","authenticated-orcid":false,"given":"Xiaomeng","family":"Yue","sequence":"first","affiliation":[{"name":"Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Epidemiology, Cincinnati Children\u2019s Hospital Medical Center"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L","family":"Hincapie","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia R","family":"Wigle","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Qiu","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Epidemiology, Cincinnati Children\u2019s Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Lovell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine"},{"name":"Division of Rheumatology, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esi M","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine"},{"name":"Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine"},{"name":"Division of Rheumatology, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff J","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"key":"2023082514344528400_keaa877-B1","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2023082514344528400_keaa877-B2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023082514344528400_keaa877-B3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023082514344528400_keaa877-B4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023082514344528400_keaa877-B5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2023082514344528400_keaa877-B6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/acr.23236","article-title":"Health-related quality of life in an inception cohort of children with juvenile idiopathic arthritis: a longitudinal analysis","volume":"70","author":"Oen","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023082514344528400_keaa877-B7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/rheumatology\/kez285","article-title":"Towards therapeutic drug monitoring of TNF inhibitors for children with juvenile idiopathic arthritis: a scoping review","volume":"59","author":"Verstegen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023082514344528400_keaa877-B8","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","article-title":"2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023082514344528400_keaa877-B9","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023082514344528400_keaa877-B10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023082514344528400_keaa877-B11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"2023082514344528400_keaa877-B12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023082514344528400_keaa877-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15140","article-title":"Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation","volume":"15","author":"Malottki","year":"2011","journal-title":"Health Technol Assess"},{"key":"2023082514344528400_keaa877-B14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/annrheumdis-2013-203936","article-title":"The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor","volume":"74","author":"Harrold","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023082514344528400_keaa877-B15","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1179-7","article-title":"Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry","volume":"18","author":"Harrold","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023082514344528400_keaa877-B16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40744-019-0149-3","article-title":"Comparative effectiveness of abatacept versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis who are anti-CCP positive in the United States Corrona registry","volume":"6","author":"Harrold","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2023082514344528400_keaa877-B17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/key433","article-title":"Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register","volume":"58","author":"Frisell","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023082514344528400_keaa877-B18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12272-014-0337-1","article-title":"Comparative effectiveness of cycling of tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-\u03b1 inhibitor using a Bayesian approach","volume":"37","author":"Kim","year":"2014","journal-title":"Arch Pharmacal Res"},{"key":"2023082514344528400_keaa877-B19","first-page":"167","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"2023082514344528400_keaa877-B20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/annrheumdis-2017-212845","article-title":"Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration","volume":"77","author":"Lauper","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023082514344528400_keaa877-B21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/jdv.15978","article-title":"Real-world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis","volume":"34","author":"Svedbom","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023082514344528400_keaa877-B22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40744-019-00177-4","article-title":"Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis","volume":"6","author":"Reed","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2023082514344528400_keaa877-B23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","author":"Horneff","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023082514344528400_keaa877-B24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2023082514344528400_keaa877-B25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"2023082514344528400_keaa877-B26","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/rheumatology\/ket248","article-title":"Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register","volume":"52","author":"McErlane","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2023082514344528400_keaa877-B27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/09546634.2019.1597244","article-title":"Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study","volume":"31","author":"Puig","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2023082514344528400_keaa877-B28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","article-title":"Clinical outcome measures in juvenile idiopathic arthritis","volume":"14","author":"Consolaro","year":"2016","journal-title":"Pediatr Rheumatol"},{"key":"2023082514344528400_keaa877-B29","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.23916","article-title":"Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis","volume":"59","author":"Magni-Manzoni","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023082514344528400_keaa877-B30","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2023082514344528400_keaa877-B31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pst.365","article-title":"Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score","volume":"9","author":"Sugihara","year":"2010","journal-title":"Pharm Stat"},{"key":"2023082514344528400_keaa877-B32","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4244\/EIJV10I6A130","article-title":"Tools & techniques-statistics: propensity score techniques","volume":"10","author":"Da Costa","year":"2014","journal-title":"EuroIntervention"},{"key":"2023082514344528400_keaa877-B33","first-page":"12","volume-title":"Multiple imputation for missing data: Concepts and new development (version 9.0)","author":"Yuan","year":"2010"},{"key":"2023082514344528400_keaa877-B34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1546-0096-12-13","article-title":"Treatment of juvenile idiopathic arthritis: a revolution in care","volume":"12","author":"Stoll","year":"2014","journal-title":"Pediatr Rheumatol"},{"key":"2023082514344528400_keaa877-B35","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2665-9913(20)30025-4","article-title":"Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study","volume":"2","author":"Kearsley-Fleet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2023082514344528400_keaa877-B36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.semarthrit.2016.06.001","article-title":"Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): analysis from the UK Childhood Arthritis Prospective Study (CAPS)","volume":"46","author":"Davies","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2023082514344528400_keaa877-B37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/phar.1856","article-title":"Use of tumor necrosis factor-alpha inhibitors in children and young adults with juvenile idiopathic arthritis or rheumatoid arthritis","volume":"36","author":"Lee","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2023082514344528400_keaa877-B38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3899\/jrheum.120753","article-title":"Methotrexate and injectable tumor necrosis factor-\u03b1 inhibitor adherence and persistence in children with rheumatic diseases","volume":"40","author":"Ringold","year":"2013","journal-title":"J Rheumatol"},{"key":"2023082514344528400_keaa877-B39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/rheumatology\/key262","article-title":"Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra","volume":"58","author":"Kearsley-Fleet","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023082514344528400_keaa877-B40","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00296-018-4041-1","article-title":"Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis","volume":"38","author":"Nikfar","year":"2018","journal-title":"Rheumatol Int"},{"key":"2023082514344528400_keaa877-B41","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10067-018-3989-2","article-title":"Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)","volume":"37","author":"Iannone","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2023082514344528400_keaa877-B42","year":"2015"},{"key":"2023082514344528400_keaa877-B43","first-page":"209","article-title":"Primary nonadherence, associated clinical outcomes, and health care resource use among patients with rheumatoid arthritis prescribed treatment with injectable biologic disease-modifying antirheumatic drugs","volume":"22","author":"Harnett","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2023082514344528400_keaa877-B44","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/MLR.0b013e318041384c","article-title":"Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis","volume":"45","author":"Grijalva","year":"2007","journal-title":"Med Care"},{"key":"2023082514344528400_keaa877-B45"},{"key":"2023082514344528400_keaa877-B46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6947-6-1","article-title":"Assessing the level of healthcare information technology adoption in the United States: a snapshot","volume":"6","author":"Poon","year":"2006","journal-title":"BMC Med Inform Decis Mak"},{"key":"2023082514344528400_keaa877-B47","author":"Huang"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaa877\/35200747\/keaa877.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/9\/4063\/51258551\/keaa877.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/9\/4063\/51258551\/keaa877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T16:56:17Z","timestamp":1692982577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/9\/4063\/6053834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,12,28]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa877","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2020,12,28]]}}}